CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Sol-Gel Technologies, Ltd.
Children's Oncology Group
UCSF Benioff Children's Hospital Oakland
UCSF Benioff Children's Hospital Oakland
UCSF Benioff Children's Hospital Oakland
PellePharm, Inc.
Columbia University
Stanford University
PellePharm, Inc.
Novartis
UCSF Benioff Children's Hospital Oakland
Novartis
Novartis